Surface Oncology, Inc. Common Stock
SURF
SURF was delisted on the 7th of September, 2023.
106 hedge funds and large institutions have $118M invested in Surface Oncology, Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 32 increasing their positions, 31 reducing their positions, and 9 closing their positions.
178% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 9
16% more funds holding
Funds holding: 91 → 106 (+15)
13% more call options, than puts
Call options by funds: $772K | Put options by funds: $684K
3% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 31
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
35% less capital invested
Capital invested by funds: $182M → $118M (-$64.2M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$4.57M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$2.03M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.62M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
+$1.1M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$3.14M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$3.1M |
| 3 |
O
OrbiMed
New York
|
-$2.85M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.06M |
| 5 |
Marshall Wace
London,
United Kingdom
|
-$1.76M |
SURF Hedge Fund Activity: Q4 2021 in Review
106 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Surface Oncology, Inc. Common Stock (SURF) for Q4 2021, worth a combined $118M — down 35% from $182M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new SURF positions and 9 closed out — a net gain of 16 holders — while 32 added to existing stakes and 31 trimmed.
The largest buyer was ARK Investment Management, adding an estimated $4.57M. The largest seller was Goldman Sachs, cutting an estimated $3.14M.
- 106 institutional investors held Surface Oncology, Inc. Common Stock (SURF) as of Q4 2021, up from 91 in Q3 2021.
- Funds reported $118M of Surface Oncology, Inc. Common Stock stock for Q4 2021, down 35% quarter-over-quarter.
- 25 funds opened new Surface Oncology, Inc. Common Stock positions in Q4 2021 and 9 closed out, a net change of +16 holders.
- The largest Surface Oncology, Inc. Common Stock buyer in Q4 2021 was ARK Investment Management, an estimated $4.57M added.
- The largest Surface Oncology, Inc. Common Stock seller in Q4 2021 was Goldman Sachs, an estimated $3.14M sold.
Based on aggregated 13F filings for Q4 2021.